Monopar Therapeutics (MNPR) Stock Forecast: StockMap's 2-Week Call
MNPR stock forecast: StockMap's model makes no two-week call on Monopar Therapeutics after the Nov 13 close: its evidence is split, 4 reasons for and 11 against. Too few two-week windows graded to judge yet.
Monopar Therapeutics last closed at $72.00, -0.94% on the session.
Against the IVW growth benchmark the position is -0.03% over the forecast window.
Monopar Therapeutics' market cap is $483.24M as of November 13, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -15 (too close to call).
Where MNPR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
14 daily calls for MNPR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Monopar Therapeutics in the 30th percentile on return on equity, where 100 is best.
Monopar Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Monopar Therapeutics as the 175th largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.
On that composite Monopar Therapeutics ranks 145th of 391 in the group, against a group median of -0.24.